BusinesseFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal ChemistryBy Nasdaq OMXApr 26, 2018, 11:31 AM UTC
BusinesseFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual MeetingBy Nasdaq OMXApr 16, 2018, 12:01 PM UTC
BusinesseFFECTOR Announces Appointment of John W. Smither to its Board of DirectorsBy Nasdaq OMXMar 23, 2018, 6:00 PM UTC
BusinessClinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety ProfileBy Nasdaq OMXDec 11, 2017, 3:00 PM UTC
BusinesseFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological EffectsBy Nasdaq OMXNov 10, 2017, 3:00 PM UTC
BusinessVaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)By Nasdaq OMXOct 26, 2017, 2:23 PM UTC
BusinesseFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal CancerBy Nasdaq OMXOct 4, 2017, 2:00 PM UTC
BusinessVaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung CancerBy Nasdaq OMXOct 6, 2016, 1:45 PM UTC
